OE @823 (99.4%) on 17-mar-2014 [ ] using eprosartan
CPL @1096 (97.1%) on 18-jan-2018 [ "_ has been used concomitantly with" "drugs called also _" "generic name is _" "_ is also sold under" "_ prevents the constriction" "Manufacturers of generic _" "_ keeps blood vessels" "_ controls high blood pressure" ] using eprosartan
CMC @1094 (96.8%) on 01-jan-2018 [ CHARS 1.27162 LASTSUFFIX=an 0.99316 PREFIX=ep 0.85634 SUFFIX=tan 0.78310 WORDSHAPE=Aaaaaaaaaa 0.71466 SUFFIX=rtan 0.69233 SUFFIX=artan 0.67616 FULL_POS=NN -0.35050 POS=NN -0.38230 WORDS -3.24012 ] using eprosartan
CPL @1098 (95.3%) on 21-jan-2018 [ "_ has been used concomitantly with" "drugs called also _" "_ is also sold under" "_ prevents the constriction" "Manufacturers of generic _" "_ controls high blood pressure" ] using eprosartan
SEAL @213 (99.8%) on 21-feb-2011 [ 123456789 ] using eprosartan
CPL @1105 (95.2%) on 25-mar-2018 [ "dosage of _" "pharmacist of _" "nursing infants from _" "tolerability of _" "many side effects of _" "you first start taking _" "doses of _" "possible side effects of _" "adult dose of _" "plasma clearance of _" "information comparing use of _" "side effects seen with _" "dosage adjustment of _" "average doses of _" "Concomitant administration of _" "dose of _" "side effects of _" "usual dose of _" "single oral dose of _" "oral dose of _" "pharmacokinetics of _" "you are taking _" "Breast-feeding—It is not known whether _" "patients receiving _" "you are allergic to _" "specific information comparing use of _" "allergic reaction to _" "elimination half-life of _" "drug interactions with _" "early treatment with _" "therapy with _" "treatment with _" "antihypertensive effect of _" "protein binding of _" "patients treated with _" "comparing use of _" "chronic use of _" "_ is excreted in" "generic name is _" "intravenous dose of _" "effects seen with _" ] using eprosartan
relations
NELL has only weak evidence for items listed in grey